Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20536082 | 0.72 | KMT2A (0.30) | KMT2A | |
| SCHEMBL10678930 | 0.60 | KMT2A (0.33) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20599484 | 0.30 | — | — | |
| SCHEMBL11120057 | 0.24 | — | — | |
| SCHEMBL247606 | 0.24 | — | — | |
| SCHEMBL31022725 | 0.24 | — | — | |
| Methane SCHEMBL23044967 | 0.24 | — | — | |
| SCHEMBL3337645 | 0.24 | — | — | |
| SCHEMBL6559802 | 0.24 | — | — | |
| Hydrogen Sulfide SCHEMBL1489554 | 0.24 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119790050-A | Oxazole TRPML1 agonists and uses thereof | 利布拉医疗公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119546588-A | Pyridine checkpoint kinase 1 (CHK 1) inhibitors and uses thereof | 无界生物公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-118488945-A | Sulfonamide ribonucleotide reductase (RNR) inhibitors and uses thereof | 无界生物公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-118434417-A | Cyclic sulfonamide ribonucleotide reductase (RNR) inhibitors and uses thereof | 无界生物公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-116507626-A | Compositions and methods for modulating short-chain dehydrogenase activity | 罗迪奥治疗公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-112939948-B | Novel quinazoline-containing compound, intermediate and application thereof | 苏州美诺医药科技有限公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-106795318-A | molecular semiconductor and polymer semiconductor and related device | 飞利斯有限公司 | 2017-05-31 | — | — | CN | disclosed |
| US-9649300-B2 | Inhibition of WNT, TGF beta and Hippo signaling pathways to treat cancer, organ fibrosis and metabolic disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160200697-A1 | INHIBITION OF WNT, TGF BETA AND HIPPO SIGNALING PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS | University of Pittsburgh - of the Commonwealth Sys tem of Higher Education (US) | 2016-07-14 | — | — | US | disclosed |
| WO-2015031109-A1 | INHIBITION OF WNT, TGF BETA AND HIPPO SIGNALING PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS | UNIVERSITY OF PITTSBURGH-OF THE COMMON WEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-03-05 | — | — | WO | disclosed |
| CN-101855323-A | Gear oil compositions, methods of making and using the same | CHEVRON USA INC | 2010-10-06 | — | — | CN | disclosed |
| CN-101842468-A | Gear oil composition, its preparation and using method | CHEVRON USA INC | 2010-09-22 | — | — | CN | disclosed |
| CN-101463286-A | Lubricant compositions with low HTHS for a given SAE viscosity grade | INFINEUM INT LTD (GB) | 2009-06-24 | — | — | CN | disclosed |
| EP-2026813-A2 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | Braincells, Inc. (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134077-A2 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| EP-1355646-A4 | MUSCARINIC RECEPTOR AGONISTS | UNIV TOLEDO (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-1355646-A1 | MUSCARINIC RECEPTOR AGONISTS | UNIVERSITY OF TOLEDO (US) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002060444-A1 | MUSCARINIC RECEPTOR AGONISTS | UNIVERSITY OF TOLEDO, THE a University instrumentality of the State of Ohio (US) | 2002-08-08 | — | — | WO | disclosed |
| CN-1008532-B | IMPROVED PROCESS FOR PREPARING STABLE OLEAGINOUS COMPOSITIONS | EXXON CHEMICAL PATENTS INC (US) | 1990-06-27 | — | — | CN | disclosed |
| CN-88103104-A | Prepare improving one's methods of stable oleaginous composition | — | 1988-12-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200697-A1 | INHIBITION OF WNT, TGF BETA AND HIPPO SIGNALING PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS | WNT1, YAP1, CTNNB1 | KMT2A 2094/4885MEN1 3101/4885NPC1 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.